MAS
IBRX icon

Meeder Advisory Services’s ImmunityBio IBRX Stock Holding History

Meeder Advisory Services’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-15,102
Closed -$37.2K – 682
2025
Q3 		$37.2K Sell
15,102
-10,033
-40% -$25.8K ﹤0.01% 622
2025
Q2 		$66.4K Buy
25,135
+9,151
+57% +$24.6K ﹤0.01% 607
2025
Q1 		$48.1K Buy
+15,984
New +$48.4K ﹤0.01% 570

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Meeder Advisory Services's IBRX Position: Q4 2025 in Review

Meeder Advisory Services sold out of ImmunityBio (IBRX) in Q4 2025, closing a stake of 15,102 shares — an estimated $37.2K sold.

Meeder Advisory Services first reported a position in IBRX in Q1 2025 and held it in 3 quarters. The position peaked at $66.4K in Q2 2025. 278 funds tracked by Wall St. Rank hold IBRX as of Q4 2025.

  • Meeder Advisory Services reported no remaining ImmunityBio position as of Q4 2025 after selling out during the quarter.
  • Meeder Advisory Services sold 15,102 ImmunityBio shares in Q4 2025, an estimated $37.2K.
  • Meeder Advisory Services first reported a position in ImmunityBio in Q1 2025 and held it in 3 quarters.
  • Meeder Advisory Services's ImmunityBio position peaked at $66.4K in Q2 2025.
  • 278 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2025.

Based on Meeder Advisory Services's 13F filing for Q4 2025, filed 11 Feb 2026.